Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S, Avet-Loiseau H. Lodé L, et al. Among authors: soussi t. Haematologica. 2010 Nov;95(11):1973-6. doi: 10.3324/haematol.2010.023697. Epub 2010 Jul 15. Haematologica. 2010. PMID: 20634494 Free PMC article.
Genetic profiling of CLL: a 'TP53 addict' perspective.
Lodé L, Cymbalista F, Soussi T. Lodé L, et al. Among authors: soussi t. Cell Death Dis. 2016 Jan 14;7(1):e2042. doi: 10.1038/cddis.2015.415. Cell Death Dis. 2016. PMID: 26775696 Free PMC article. No abstract available.
TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F. Lazarian G, et al. Among authors: soussi t. Int J Cancer. 2016 Oct 15;139(8):1759-63. doi: 10.1002/ijc.30222. Epub 2016 Jun 24. Int J Cancer. 2016. PMID: 27270786
TP53 and 53BP1 Reunited.
Soussi T, Kroemer G. Soussi T, et al. Trends Cell Biol. 2017 May;27(5):311-313. doi: 10.1016/j.tcb.2016.10.004. Epub 2016 Nov 17. Trends Cell Biol. 2017. PMID: 27866833 Free article.
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Leroy B, et al. Among authors: soussi t. Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Cancer Res. 2017. PMID: 28254861 Free PMC article. Review.
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.
Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P. Lodé L, et al. Among authors: soussi t. Haematologica. 2018 Apr;103(4):e143-e146. doi: 10.3324/haematol.2017.181404. Epub 2017 Dec 21. Haematologica. 2018. PMID: 29269520 Free PMC article. No abstract available.
228 results